The Role of EEG in Identifying Cognitive Changes in Parkinson's Disease

NCT ID: NCT06145776

Last Updated: 2023-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-02

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a group controlled clinical trial. Parallel study, patients aged 40-80 years, with Parkinson disease. Twelve sessions, three times a week, for 30 minutes. Training will consist of Transcranial Direct Current Stimulation linked to tredmill training, in 3 blocks of 7 minutes, and adicionally to the Experimental Group, dual-task cognitive-motor exercises, simultaneously. The investigators will use the folowwing instruments: Auditory Stroop Test, Trail Making Test, Montreal Cognitive Assessment, Timed-up-and-go ST and DT, UPDRS II and III and Eletroencefalography (EEG). The objective is to examine cognitive alterations on PD pacients due to intervention and the relationships between baseline outcomes in responders and non-responders to therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Parkinson disease (PD) is one of the most common age-related brain disorders. PD is defined primarily as a movement disorder, with the typical symptoms being resting tremor, rigidity, bradykinesia and postural instability. In addition to the defining dopamine-related motor symptoms, however, PD is increasingly recognized as a heterogeneous multisystem disorder involving other neurotransmitter systems, such as the serotonergic, noradrenergic and cholinergic circuits. Thus, a wide variety of nonmotor symptoms (NMS) linked with these neurotransmitters are commonly observed in patients with PD. Cognitive decline is among the most common and important NMS. Robust evidence indicates that in comparison with age-matched groups without PD, people with PD exhibit more rapid decline in a number of cognitive domains - in particular, executive, attentional and visuospatial domains, but also memory. In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. A variety of biomarkers have been studied, some using novel structural and functional imaging techniques, and have documented in vivo brain changes associated with cognitive impairment. Patients with Parkinson's disease have difficulty performing a dual-task, a condition present in everyday life. It is possible that strategies such as Transcranial Direct Current Stimulation can be associated with motor training enriched with dual-task and cognitive training to improve the performance of two concurrent tasks. It is currently unclear whether specific tasks and clinical conditions of PD patients have different results after the intervention. Therefore, the proposed randomized controlled trial will examine the effects of a intervention protocol on brain eletric activity and cognitive outcomes on PD patientes and the relationships between baseline outcomes in responders and non-responders to therapy.

Discussion: This study will evaluate the effectiveness of an intervention protocol with transcranial direct current stimulation, dual-task motor-cognitive training in patients with Parkinson's disease. The study will also highlight whether, by qEEG analysis, the clinical factors and variability between individuals that could interfere in the efficacy intervention and influence the therapeutic effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Cognition Disorder EEG With Abnormally Slow Frequencies

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Parkinson; EEG; cognition; dual-task cost

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study is a randomized, double-blind, group controlled clinical trial. Parallel study,
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Participants will be randomly allocated, using an online generator (www.random.org), into two groups (1:1): CG) tDCS active + gait training; EG) tDCS active + gait training + dual-task. This sequence will be performed independently and remotely by a blinded investigator, who will have no knowledge of other study procedures. The concealed allocation process will be conducted using sequentially numbered sealed opaque envelopes. The outcome assessors and patients will be blinded to the procedures.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dual-task group

Dual-Task Training Protocol (DTTP) The dual-task training protocol (DT) will consist in cognitive exercise categories: verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks, which will be associated to treadmill gait training (Sousa et al., 2016). Verbal commands will focus on the following: (1) large strides; (2) heel strike; (3) raising the knees while walking (Kelly et al., 2012).

Group Type EXPERIMENTAL

tDCS + tredmill training (Standart trehab training)

Intervention Type OTHER

Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.

Cognitite-motor Dual Task Training (DT training)

Intervention Type OTHER

The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)

control group

The participants will perform 21 min treadmill gait training associated to tDCS active in F3 for 20 min, 3 times a week for 4 weeks.

Group Type ACTIVE_COMPARATOR

tDCS + tredmill training (Standart trehab training)

Intervention Type OTHER

Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tDCS + tredmill training (Standart trehab training)

Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.

Intervention Type OTHER

Cognitite-motor Dual Task Training (DT training)

The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* being diagnosed with idiopathic Parkinson's disease by a neurologist based on definitive evidence of responsiveness to levodopa at the start of the disease and the history of progressive hypokinesia with asymmetric onset. PD will be diagnosed based on Parkinson's Disease Society Brain Bank (PDSBB) criteria, as described in Hughes et al. (1992)
* Age between 40 and 70 years, with no distinction for sex, schooling level or other sociodemographic characteristics;
* disease staging between 1.5 and 3, according to the modified Hoehn and Yahr scale (Hoehn and Yahr, 1998);
* undergoing regular pharmacological treatment with levodopa (equivalent dose \> 300 mg) or taking antiparkinsonian medication, such as anticholinergics, selegiline, dopamine agonists, and COMT (catechol-O-methyl transferase) inhibitors for at least 4 weeks prior intervention;
* score of more than 24 points on the Mini-Mental State Examination (Folstein et al., 1975);
* not exhibiting other associated neurological diseases; and
* no musculoskeletal and/or cardiorespiratory changes that could compromise gait.

Exclusion Criteria

* diagnosis of atypical Parkinson's disease;
* neuropsychiatric comorbidities;
* convulsions, metal clips and/or pacemaker;
* deep brain stimulation implant;
* history of epilepsy; neurosurgery;
* traumatic brain injury;
* alcohol abuse or drug dependency;
* associated diseases of the peripheral or central nervous system;
* undergoing physical therapy at another location;
* inability to walk 10 meters;
* presence of important dyskinesia that prevents the participant from sitting in a chair;
* abnormal and persistent increase in systemic blood pressure before or during training, after three measurements taken 5 min apart-Cut-off: systolic blood pressure ≥ 140 mm Hg and/or diastolic ≥ 90 mm Hg (Malachias et al., 2016);
* not understanding any of the training protocol stages; chemical scalp treatment within the previous 30 days, and experiencing severe pain and/or discomfort that precludes performing the proposed activities.
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal University of Paraíba

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Suellen Andrade

Suellen Marinho Andrade, Federal University of Paraíba

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Suellen Andrade, Doctor

Role: PRINCIPAL_INVESTIGATOR

Federal University of Paraiba

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Federal University of Paraiba

João Pessoa, Paraíba, Brazil

Site Status RECRUITING

Aging and Neuroscience Studies Laboratory

João Pessoa, , Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Suellen M Andrade, Doctor

Role: CONTACT

Phone: 83993812744

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Suellen M Marinho dos Santos Andrade, Doctor

Role: primary

E

Role: backup

Suellen Andrade

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Costa-Ribeiro A, Andrade SMMDS, Ferrer MLV, Silva OAPD, Salvador MLS, Smaili S, Lindquist ARR. Can Task Specificity Impact tDCS-Linked to Dual Task Training Gains in Parkinson's Disease? A Protocol for a Randomized Controlled Trial. Front Aging Neurosci. 2021 Jul 1;13:684689. doi: 10.3389/fnagi.2021.684689. eCollection 2021.

Reference Type BACKGROUND
PMID: 34276344 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EEG_DPcog

Identifier Type: -

Identifier Source: org_study_id